Research Paper Volume 14, Issue 17 pp 7170—7185
A circadian rhythm-related gene signature for predicting relapse risk and immunotherapeutic effect in prostate adenocarcinoma
Figure 2. Evaluation of the performance of the gene signature. (A) AUC for predicting three-year RFS is 0.852 in the training set (n=236). (B) AUC for predicting three-year RFS is 0.856 in the validation set (n=102). (C) Low-risk patients had an improved RFS than high-risk patients in the training set. (D) Low-risk patients had an improved RFS than high-risk patients in the validation set.